Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 91 to 100 of 281 total matches.
Gepirone (Exxua) for Depression
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
at risk should
be followed closely in the first weeks to months
of treatment.
DRUG INTERACTIONS — Use ...
The FDA has approved an oral extended-release
formulation of gepirone (Exxua – Fabre-Kramer), a
selective 5-HT1A receptor agonist, for treatment of
major depressive disorder (MDD) in adults. Gepirone
was originally developed decades ago for treatment
of anxiety and depression, but it was not approved by
the FDA for such use. Gepirone is structurally related
to buspirone, which is FDA-approved for treatment
of anxiety.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):97-9 doi:10.58347/tml.2024.1705a | Show Introduction Hide Introduction
Ritlecitinib (Litfulo) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
have been reported with use of JAK inhibitors.
Drug Interactions: Use of ritlecitinib with strong CYP3A inducers ...
The FDA has approved ritlecitinib (Litfulo – Pfizer), an
oral JAK and TEC kinase family inhibitor, for treatment
of severe alopecia areata in patients ≥12 years old.
Ritlecitinib is the second oral drug to be approved
in the US for treatment of severe alopecia areata;
baricitinib (Olumiant), a JAK inhibitor, is approved
only for use in adults.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):185-6 doi:10.58347/tml.2023.1690a | Show Introduction Hide Introduction
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022 (Issue 1660)
with topical ruxolitinib.
DRUG INTERACTIONS ― Ruxolitinib is a substrate
of CYP3A4; concomitant use ...
The 1.5% cream formulation of the Janus kinase
(JAK) inhibitor ruxolitinib (Opzelura – Incyte) has
been approved by the FDA for topical treatment of
nonsegmental vitiligo (NSV) in patients ≥12 years old.
Opzelura is the first product to be approved by the
FDA for this indication. It was previously approved for
treatment of atopic dermatitis.
Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
have been reported
with use of BTK inhibitors.
DRUG INTERACTIONS – Pirtobrutinib is a CYP3A
substrate; concurrent ...
The Bruton's tyrosine kinase (BTK) inhibitor
pirtobrutinib (Jaypirca – Lilly) has received
accelerated approval from the FDA for treatment of
relapsed or refractory mantle cell lymphoma (MCL) in
adults who received ≥2 prior lines of systemic therapy,
including a BTK inhibitor. Accelerated approval was
based on the response rate. The BTK inhibitors
ibrutinib (Imbruvica), acalabrutinib (Calquence),
and zanubrutinib (Brukinsa) are also approved for
treatment of MCL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e35-6 doi:10.58347/tml.2023.1670f | Show Introduction Hide Introduction
COVID-19 Update: Metformin to Prevent Long Covid?
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
is not recommended.
DRUG INTERACTIONS – Metformin is a substrate of
organic cation transporter 1 (OCT1 ...
Results from a double-blind trial suggest that off-label
use of the oral antihyperglycemic drug metformin
in patients with COVID-19 may decrease the risk
of post-acute sequelae of SARS-CoV-2 infection
("long COVID").
Med Lett Drugs Ther. 2023 May 29;65(1677):87-8 doi:10.58347/tml.2023.1677e | Show Introduction Hide Introduction
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
, benzodiazepines, barbituates, or
antiseizure drugs.
Drug Interactions: May interact with many other drugs ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
are available at www.
warfarindosing.org.
Drug Interactions – Maintaining the INR within
the desired range ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
Tramadol/Celecoxib (Seglentis) for Pain
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022 (Issue 1648)
hepatitis has occurred with use of celecoxib.
DRUG INTERACTIONS — Tramadol is metabolized
by CYP2D6 to M1 ...
The FDA has approved Seglentis (Esteve/Kowa), an
oral combination of tramadol hydrochloride, a weak
opioid agonist and weak serotonin and norepinephrine
reuptake inhibitor (SNRI), and celecoxib, a COX-2
selective nonsteroidal anti-inflammatory drug
(NSAID), for use in adults with acute pain that is
severe enough to require an opioid and for which
alternative treatment options are inadequate.
Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
is not clear.
DRUG INTERACTIONS – Bremelanotide may slow
gastric emptying and alter the rate and extent ...
The FDA has approved bremelanotide (Vyleesi – Amag),
a melanocortin receptor agonist, for subcutaneous
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide is not approved for use in men or
postmenopausal women. It is the second drug to
be approved in the US for this indication; flibanserin
(Addyi), which was approved in 2015, was the first.
Zavegepant (Zavzpret) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
may be needed for renal or hepatic impairment or for drug interactions.
2. Approximate WAC for one dose ...
The FDA has approved zavegepant nasal spray
(Zavzpret – Pfizer) for acute treatment of migraine
with or without aura in adults. Zavzpret is the first
nasal spray formulation of a calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant") to
become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8 doi:10.58347/tml.2023.1681c | Show Introduction Hide Introduction